AlphAIalphai — Financial news for AI agents
rttnews.comJUL 293 min read$IART

Integra LifeSciences Swings To Profit In Q2; Trims FY26 Revenue Outlook

Integra LifeSciences (IART) reported Q2 net earnings of $4.48 million, or $0.06 per share, versus a year-ago net loss. Adjusted EPS was $0.56. Revenue rose 0.8% to $418.76 million. For Q3, it expects adjusted EPS of $0.53-$0.61 on $410-$425 million revenue. For FY26, it trimmed revenue guidance to $1.654-$1.695 billion and reiterated adjusted EPS of $2.40-$2.50.

Original reporting
rttnews.com
Published Jul 29, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 2:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Integra LifeSciences Swings To Profit In Q2; Trims FY26 Revenue Outlook — source image
Source · rttnews.com
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

The key trade input is the combination of (1) Q2 adjusted EPS improvement, (2) Q3 adjusted EPS and revenue range guidance, and (3) FY26 revenue guidance reduction while maintaining FY26 adjusted earnings range.

02

Market read

Traders can reassess near-term expectations using the explicit Q3 adjusted EPS and revenue ranges and reprice FY26 revenue expectations after the FX-related guidance trim.

03

What to watch

Investors may focus more on SurgiMend relaunch execution timing and Braintree ramp than on the FX-driven revenue range reduction.

Relevance 7/10Novelty 6/10Timing: pre-market after Q2 earnings and updated Q3/FY26 guidance

Background

Integra LifeSciences posted Q2 results and updated forward guidance, including a revenue outlook trim attributed to stronger U.S. dollar effects on foreign exchange rates.

Company-level read

Ticker impact

$IARTNeutralMedium confidence
Context

Integra LifeSciences reported Q2 adjusted EPS of $0.56 vs $0.45 prior year and trimmed FY26 revenue guidance to $1.654B-$1.695B.

Expected impact

Near-term volatility likely as revenue outlook narrows, partially offset by maintained FY26 adjusted EPS range and operational progress.

Evidence & confidence

The article provides fresh quarterly results, explicit Q3 and FY26 guidance ranges, and a specific reason for the revenue outlook change (stronger U.S. dollar).

Market effects

Sector

Medical device peers may see read-across on FX sensitivity and the credibility/timing of surgical product relaunches.

Regional

Stronger U.S. dollar headwind highlighted, relevant for companies with foreign revenue exposure.

Global

FX-driven guidance adjustments can influence broader medtech earnings expectations for multinational revenue streams.

Counterpoint

What could challenge this read

The revenue guidance trim is FX-related, while adjusted earnings guidance remains in a similar band, suggesting limited fundamental deterioration.

Key entities

  • company
    Integra LifeSciences Holdings Corp.

    Reported Q2 earnings, provided Q3 and FY26 guidance, initiated production at Braintree, and reiterated SurgiMend relaunch plans.

Read at source← All news

Related articles

AUG 5
$IARTMed

Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, roughly flat year over year and slightly above estimates, with adjusted EPS of $0.56 vs $0.48 expected. Management cited reimbursement pressures and product mix for margin compression, while adjusted EPS outperformance reflected execution and tariff dynamics. Full-year revenue guidance was reconfirmed at $1.67B midpoint and adjusted EPS at $2.45.

financialcontent.com4 min
AUG 1
$IARTMed

IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook

Integra LifeSciences (IART) reported Q2 revenue of $418.8M, flat YoY and slightly above estimates, with adjusted EPS of $0.56 (vs $0.48) and adjusted EBITDA of $78.41M. Operating margin fell to 4.6%. The company reconfirmed FY revenue guidance of $1.67B and adjusted EPS of $2.45, citing cost savings and operational realignment amid reimbursement and competitive pressures.

finance.yahoo.com6 min
JUL 30
$IARTMedAI 8/10

Integra LifeSciences Q2 Earnings Call Highlights

Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share. "We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds," Knight said.

yahoo.com6 min
JUL 29
$IARTMedAI 8/10

Why Integra LifeSciences (IART) Shares Are Sliding Today

Integra LifeSciences (IART) shares fell 10.1% after Q2 results. The company reported adjusted EPS of $0.56 above estimates, but revenue was flat at $418.8 million and operating margin fell to 4.6% from 7.9%. Q3 revenue guidance was about $417.5 million, and full-year revenue guidance was reconfirmed.

financialcontent.com6 min
JUL 29
$IARTMedAI 8/10

Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra LifeSciences Holdings (Nasdaq: IART) reported Q2 2026 results for the quarter ended June 30. Revenues were $418.8M, up 0.8% reported. GAAP diluted EPS was $0.06 versus $(6.31) a year earlier; adjusted EPS was $0.56 versus $0.45. The company updated 2026 reported revenue guidance to $1.654B-$1.695B and reaffirmed organic growth of 0.8%-3.3% and adjusted EPS of $2.40-$2.50.

finanznachrichten.de6 min